Study of ALX2004 for advanced solid tumors
Part of Cancer, Digestive system, Lungs & breathing clinical trials.
This trial tests a new drug, ALX2004, for people with certain advanced cancers (head and neck, lung, esophagus, or colorectal) that have stopped responding to standard treatments. The goal is to see if the drug is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these cancers: head and neck, lung, esophagus, or colorectal cancer, and it has spread or come back and cannot be surgically removed.
- Your cancer has gotten worse after at least one prior treatment, and no standard therapy is available for your situation.
- For certain cancer types, you have had a limited number of prior treatments (e.g., no more than 2-4 lines of therapy depending on your cancer).
- You are in generally good health, with adequate blood cell counts, kidney and liver function, and ability to perform daily activities.
- You have not had a prior ADC (antibody-drug conjugate) that targets TOP1 (a specific enzyme).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HLX37 combined with chemotherapy for people with advanced non-small cell lung cancer that cannot be removed by surgery or has spread. The goal is to see if the combination is safe and works better than chemotherapy alone.
This trial tests a new drug called ALK201 combined with an immunotherapy drug (ivonescimab) for people with squamous non-small cell lung cancer. The goal is to see if this combination can shrink tumors and is safe.
This is an early-stage study testing a new cancer drug called EXS74539 to find the right dose and see how well it works in people with various advanced solid tumors. The drug may help patients whose cancers have stopped responding to standard treatments.
This trial tests a new drug called ADRX-0405 in people with advanced solid tumors like prostate, stomach, or lung cancer. The goal is to see how safe it is and if it shrinks tumors.
This trial tests a new drug called HLX43 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It aims to find safe dosing and understand how the drug works in the body.
This trial tests a new drug called HLX42 for people with advanced solid tumors (including a type of lung cancer called NSCLC) who have no good treatment options left. The goal is to see if it's safe and if it can help shrink tumors.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.